JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

JAMA Network - Podcast tekijän mukaan The JAMA Network

kokeile Podimo ilmaiseksi 30 päivän ajan

universumia joka on täynnä satoja podcasteja ja äänikirjoja, klikkaa tätä kokeillaksesi

Sponsored

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Visit the podcast's native language site